Skip to main content
Journal cover image

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.

Publication ,  Journal Article
Riedel, RF; Febbo, PG
Published in: Future Oncol
August 2005

Despite advances in chemotherapeutics, overall survival for advanced lung cancer patients remains poor. Consequently, efforts have focused on the use of targeted therapies to improve response rates and survival. The epidermal growth factor receptor (EGFR) is overexpressed in a variety of cancers, including lung, and may play a critical role in the pathogenesis of disease. Small molecule tyrosine kinase inhibitors, such as gefitinib (Iressa(R)), have response rates of between 10 and 27% in Phase II trials, and anecdotal reports of dramatic and sustained responses. Two recent studies published simultaneously, identified mutations in the ATP-binding cleft of the EGFR that are associated with clinical response to gefitinib. This finding has extraordinary implications and serves as a critical step toward individualized, patient-specific treatment plans based on the molecular constitution of the tumor of each individual.

Duke Scholars

Published In

Future Oncol

DOI

ISSN

1479-6694

Publication Date

August 2005

Volume

1

Issue

4

Start / End Page

461 / 466

Location

England

Related Subject Headings

  • Quinazolines
  • Oncology & Carcinogenesis
  • Mutation
  • Lung Neoplasms
  • Humans
  • Gefitinib
  • ErbB Receptors
  • Drug Resistance, Neoplasm
  • Clinical Trials as Topic
  • Carcinoma, Non-Small-Cell Lung
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Riedel, R. F., & Febbo, P. G. (2005). Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. Future Oncol, 1(4), 461–466. https://doi.org/10.2217/14796694.1.4.461
Riedel, Richard F., and Phillip G. Febbo. “Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.Future Oncol 1, no. 4 (August 2005): 461–66. https://doi.org/10.2217/14796694.1.4.461.
Riedel, Richard F., and Phillip G. Febbo. “Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.Future Oncol, vol. 1, no. 4, Aug. 2005, pp. 461–66. Pubmed, doi:10.2217/14796694.1.4.461.
Journal cover image

Published In

Future Oncol

DOI

ISSN

1479-6694

Publication Date

August 2005

Volume

1

Issue

4

Start / End Page

461 / 466

Location

England

Related Subject Headings

  • Quinazolines
  • Oncology & Carcinogenesis
  • Mutation
  • Lung Neoplasms
  • Humans
  • Gefitinib
  • ErbB Receptors
  • Drug Resistance, Neoplasm
  • Clinical Trials as Topic
  • Carcinoma, Non-Small-Cell Lung